Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant BCG-dltA
- Development stage
- Preclinical
- Lead developer
- Chungang University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravesical
01
Overview
recombinant BCG-dltA is a genetically modified strain of Bacillus Calmette-Guérin (BCG) engineered to express the dltA gene (D-alanyl carrier protein ligase). Developed by researchers at Chung-Ang University and the National Cancer Center in South Korea, this recombinant BCG strain is designed to treat BCG-unresponsive bladder cancer (BUBC) and non-muscle-invasive bladder cancer (NMIBC). The dltA gene confers resistance to cationic antimicrobial peptides (AMPs) secreted by urothelial and immune cells by D-alanylation of lipoteichoic acids, which increases the bacterial surface charge and reduces AMP binding. This modification enhances the survival, persistence, and internalization of the bacterium in bladder cancer cells, leading to increased release of antitumor cytokines (such as IL-6, IL-12, TNF-alpha, and IFN-gamma) and enhanced recruitment of immune cells like monocytes. It is administered intravesically and has been studied both as a monotherapy and in combination with immune checkpoint inhibitors like pembrolizumab.
- Other names
- rBCG-dltArecombinant Bacillus Calmette-Guerin-dltArecombinant Bacillus Calmette-Guérin containing dltArecombinant Bacillus Calmette-Guérin-dltA
Beyond the preview
Go deeper on recombinant BCG-dltA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant BCG-dltA.